Non-Invasive Pre-Biopsy Screening for Clinically Significant Prostate Cancer
Sub-theme: Healthcare Technologies and Devices of the Future
Led by: Heriot-Watt University
In Collaboration with: University of Edinburgh
Contact: Professor Bob Reuben, Heriot-Watt University
Summary:
IntelliPalp Dx Ltd was established in 2020 as a spin-out from Heriot-Watt University and University of Edinburgh, researching, designing and manufacturing diagnostic devices for a world market. CENSIS is working with IntelliPalp to accelerate the process of bringing the test to market and, with help from the Medical Device Manufacturing Centre (MDMC), IntelliPalp is designing and making a prototype for use in a multi-centre validation trial.
There are 47,500 diagnoses each year for prostate cancer – equivalent to 129 every day – while as many as one in eight men develop the disease in their lifetime. Currently, a positive diagnosis with a prostate-specific antigen (PSA) test and subjective Digital Rectal Exam (DRE) leads to multi-parametric magnetic resonance imaging (mpMRI) scan and then biopsy for suspected cancer. ProstaPalp® is an objective, instant and simple test which supplements DRE and avoids the expense and delay of mpMRI. ProstaPalp® uses a patented method of dynamic mechanical measurement obtained from a finger-mounted probe, giving instant results in primary care.
ProstaPalp is a great example of the growing and evolving role that sensors play in the healthcare sector. Deliverable at the earliest and most anxious stage of the process of diagnosing prostate cancer, it will have a significant positive impact on patient experience and help health services better focus attention and resources. The test will also allow a technology researched, designed, and made in Scotland to realise global impact and benefit.
Non-Invasive Pre-Biopsy Screening for Clinically Significant Prostate Cancer - Case Study PDF